IL2 and systemic lupus erythematosus: The researchers summarized data from proof-of-concept clinical trials, which showed that, at low doses, IL-2 is well tolerated and induces regulatory T cells to address immune imbalances in patients with lupus, type 1 diabetes and other autoimmune disorders.